MedPath

Establishment of treatment regimen to eradicate H. pylori infection in patients who failed 1st-line and 2nd-line therapy.

Not Applicable
Conditions
Helicobacter pylori-associated gastritis
Registration Number
JPRN-UMIN000013594
Lead Sponsor
Hirosaki University Graduate School of Medicine
Brief Summary

The eradication rate of PCAB-AMOX-STFX was 85.7% (42/49; 95% CI, 75.9-95.5%) by intention-to-treat analysis and 87.5% (42/48; 78.4-96.9%) by per protocol analysis. Eradication was unsuccessful in one of two patients whose strains had low sensitivity to AMOX and three patients whose strains were resistant to STFX In contrast, eradication therapy was successful in 13 patients infected with strains which were sensitive to both AMOX and STFX.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

who did not agree

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eradication rate
Secondary Outcome Measures
NameTimeMethod
side effects
© Copyright 2025. All Rights Reserved by MedPath